Tumor-specific Th17-polarized cells eradicate large established melanoma.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2007-11-120998PMID 18354038PMCID PMC2442746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Center for Biotechnology Information

  2008cited by this paper
• Regulation of IL-17 production in human lymphocytes.

  2008cited by this paper
• IFN-gamma mediates the death of Th1 cells in a paracrine manner.

  2008cited by this paper
• Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.

  2008cited by this paper
• IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.

  2008cited by this paper
• IFN-γ Mediates the Death of Th1 Cells in a Paracrine Manner1

  2008cited by this paper
• IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

  2008cited by this paper
• T(H)-17 differentiation: of mice and men.

  2007cited by this paper
• Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.

  2007cited by this paper
• TH1 cells control themselves by producing interleukin-10

  2007cited by this paper
• Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation.

  2007cited by this paper
• Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1

  2007cited by this paper
• Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells

  2007cited by this paper
• Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells

  2007cited by this paper
• IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner*

  2007cited by this paper
• Interleukin-10 production by effector T cells: Th1 cells show self control

  2007cited by this paper
• Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation.

  2007cited by this paper
• IL-17 family cytokines and the expanding diversity of effector T cell lineages.

  2007cited by this paper
• Differentiation and function of Th17 T cells.

  2007cited by this paper
• Experimental and clinical approaches for optimization of the graft-versus-leukemia effect

  2007cited by this paper
• TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1

  2007cited by this paper
• Swords into plowshares: IL-23 repurposes tumor immune surveillance.

  2007cited by this paper
• Phenotypic and functional features of human Th17 cells

  2007cited by this paper
• IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells

  2007cited by this paper
• Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-121

  2007cited by this paper
• A cytokine-mediated link between innate immunity, inflammation, and cancer.

  2007cited by this paper
• TH-17 cells in the circle of immunity and autoimmunity

  2007cited by this paper
• IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

  2007cited by this paper
• Transcriptional regulation of Th17 cell differentiation.

  2007cited by this paper
• Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment

  2007cited by this paper
• Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

  2007cited by this paper
• An interferon-γ-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis

  2007cited by this paper
• Phenotypic and functional features of human Th 17 cells

  2007cited by this paper
• T-bet Regulates the Fate of Th1 and Th17 Lymphocytes in Autoimmunity1

  2007cited by this paper
• Genomic anatomy of the Tyrp1 (brown) deletion complex.

  2006cited by this paper
• Cancer Immunol Immunother DOI 10.1007/s00262-006-0194-y REVIEW

  2006cited by this paper
• Interferons, immunity and cancer immunoediting

  2006cited by this paper
• T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17

  2006cited by this paper
• Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease

  2006cited by this paper
• Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

  2006cited by this paper
• IL-23 promotes tumour incidence and growth

  2006cited by this paper
• Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant1

  2006cited by this paper
• CCR6 and CCL20

  2006cited by this paper
• The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

  2006cited by this paper
• Transforming growth factor-beta induces development of the T(H)17 lineage.

  2006cited by this paper
• Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.

  2006cited by this paper
• Interplay between RORgammat, Egr3, and E proteins controls proliferation in response to pre-TCR signals.

  2006cited by this paper
• CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

  2005cited by this paper
• Tim-3+ T-bet+ Tumor-Specific Th1 Cells Colocalize with and Inhibit Development and Growth of Murine Neoplasms1

  2005cited by this paper
• Immunological ignorance of solid tumors

  2005cited by this paper
• A critical function for type I interferons in cancer immunoediting

  2005cited by this paper
• Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

  2005cited by this paper
• CD4 T cells in tumor immunity

  2005cited by this paper
• CD4 cells can be more efficient at tumor rejection than CD8 cells.

  2005cited by this paper
• IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis1

  2005cited by this paper
• Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

  2005cited by this paper
• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  2005cited by this paper
• CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

  2005cited by this paper
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

  2005cited by this paper
• Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

  2005cited by this paper
• Primary antitumor immune response mediated by CD4+ T cells.

  2005cited by this paper
• CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors1

  2004cited by this paper
• Expression and activity of IL‐17 in cutaneous T‐cell lymphomas (mycosis fungoides and sezary syndrome)

  2004cited by this paper
• Loss of T-bet, But Not STAT1, Prevents the Development of Experimental Autoimmune Encephalomyelitis

  2004cited by this paper
• Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.

  2004cited by this paper
• Expression and function of pro‐inflammatory interleukin IL‐17 and IL‐17 receptor in normal, benign hyperplastic, and malignant prostate

  2003cited by this paper
• Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

  2003cited by this paper
• The CC chemokine CCL20 and its receptor CCR6.

  2003cited by this paper
• Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells

  2003cited by this paper
• Interleukin-17 promotes angiogenesis and tumor growth.

  2003cited by this paper
• Articles on similar topics can be found in the following Blood collections

  2002cited by this paper
• Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.

  2002cited by this paper
• Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell.

  2002cited by this paper
• Decision making in the immune system: The lineage decisions of helper T cells

  2002cited by this paper
• Generation of antigen-specific, lacZ-inducible T-cell hybrids.

  2001cited by this paper
• Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.

  2001cited by this paper
• Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis.

  2000cited by this paper
• Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis

  2000cited by this paper
• The critical role of Th1-dominant immunity in tumor immunology

  2000cited by this paper
• CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

  2000cited by this paper
• CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

  2000cited by this paper
• Requirement for RORgamma in thymocyte survival and lymphoid organ development.

  2000cited by this paper
• Immune surveillance against a solid tumor fails because of immunological ignorance.

  1999cited by this paper
• Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice.

  1999cited by this paper
• Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo

  1999cited by this paper
• CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

  1999cited by this paper
• Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

  1999cited by this paper
• CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

  1999cited by this paper
• T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.

  1998cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells.

  1998cited by this paper
• The allogeneic CD4+ T-cell-mediated graft-versus-leukemia effect.

  1997cited by this paper
• Cellular responses to interferon-gamma.

  1997cited by this paper
• Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies

  1995cited by this paper
• In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

  1994cited by this paper
• The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.

  1993cited by this paper
• The role of tumor-specific Lyt-1+2− T cells in eradicating tumor cells in vivo

  1987cited by this paper
• Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

  1986cited by this paper
• Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

  1985cited by this paper
• The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

  1984cited by this paper

• Regulatory Mechanisms and Functions of RORγt⁺ Antigen-Presenting Cells in the Tumor Microenvironment of Non-Small Cell Lung Cancer.

  2026cites this paper
• Contextualizing TH17 cells in cancer.

  2026cites this paper
• The immunology of vitiligo.

  2026cites this paper
• Immunological Functions of Th17 cells in Colon Cancer: From Pathogenic Mechanisms to Emerging Treatments.

  2026cites this paper
• Diagnostic Efficacy and Clinical Significance of Lymphocyte Subsets, Granzyme B and Perforin in the Peripheral Blood of Patients with Invasive Breast Cancer Following Neoadjuvant Chemotherapy

  2025cites this paper
• Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

  2025cites this paper
• Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors

  2025cites this paper
• Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity

  2025cites this paper
• Yiqi Jianpi Kangai Decoction Enhances the Chemotherapy Effect by Inducing Apoptosis and Regulating Treg and Th17 Cells in Colorectal Cancer Mice Model with Spleen Qi Deficiency

  2025cites this paper
• The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs

  2025cites this paper
• Dermal dilemma: Not your usual granuloma.

  2025cites this paper
• Deciphering Depigmentation: Mouse Models for Vitiligo Research.

  2025cites this paper
• T-helper Transcription Factor Profiling in Peripheral Blood Mononuclear Cells: A Non-invasive Approach to Predicting Disease Stage in Breast Cancer.

  2025cites this paper
• A New Method of Canine CD4+ T Lymphocyte Differentiation Towards the Th17 Phenotype with Analysis of Properties and Mitochondrial Activity

  2025cites this paper
• Calcitriol and Tacalcitol Modulate Th17 Differentiation Through Osteopontin Receptors: Age-Dependent Insights from a Mouse Breast Cancer Model

  2025cites this paper
• HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages

  2025cites this paper
• Prognostic impact of serum interleukin-6 and 17 level in patients with bladder cancer: a systematic review and meta-analysis

  2025cites this paper
• A Novel RORγ-Selective Agonist Facilitates the Infiltration of Effector T Cells and Innate Immune Cells into Tumor Tissue, Demonstrating Antitumor Efficacy.

  2025cites this paper
• ProS1-MerTK signaling in CD4 T cells: implications for TIL expansion and functionality

  2025cites this paper
• Recent advances in the role of high-salt diet in anti- and pro-cancer progression

  2025cites this paper
• Activated STING in the thymic epithelium alters T cell development and selection leading to autoimmunity

  2025influential citation
• Immunological enhancement of micro-nanoparticle formulated with risedronate and zinc as vaccine adjuvant in aged mice

  2025cites this paper
• Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis.

  2025cites this paper
• Molecular Mechanism for the Selective Presentation of Antigenic Peptides by Major Histocompatibility Complex Class I and Class II Molecules: A Hypothesis

  2025cites this paper
• Dendritic Cells at the Center of Reactive Tumor Immunity

  2025cites this paper
• Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment

  2025cites this paper
• Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.

  2024cites this paper
• IFNγ at the early stage induced after cryo-thermal therapy maintains CD4+ Th1-prone differentiation, leading to long-term antitumor immunity

  2024cites this paper
• Evaluation of the Activity of Cardiac Glycosides on RORγ and RORγT Nuclear Receptors.

  2024cites this paper
• Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma

  2024cites this paper
• Therapeutic potential of interleukin-21 in cancer

  2024cites this paper
• Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer.

  2024cites this paper
• Deciphering CD4+ T cell‐mediated responses against cancer

  2024cites this paper
• One CD4+TCR and one CD8+TCR targeting autochthonous neoantigens are essential and sufficient for tumor eradication.

  2024cites this paper
• Activated STING in the thymus alters T cell development and selection leading to autoimmunity

  2024influential citation
• Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response.

  2024cites this paper
• Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia

  2024cites this paper
• The type 2 inflammatory response favors recognition of tumor antigens by IgE in breast cancer

  2024cites this paper
• Animal models unraveling the complexity of vitiligo pathogenesis.

  2024cites this paper
• Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target

  2024cites this paper
• Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events

  2024cites this paper
• Cytokines in cancer.

  2024cites this paper
• The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review

  2024cites this paper
• Harnessing innate immune pathways for therapeutic advancement in cancer

  2024cites this paper
• High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following Transplant.

  2024cites this paper
• Elevated levels of peripheral Th17 cells and Th17-related cytokines in patients with periampullary adenocarcinoma.

  2024cites this paper
• TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models

  2024cites this paper
• Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?

  2024cites this paper
• Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models

  2024cites this paper
• An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model

  2024cites this paper
• Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma

  2024cites this paper
• CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy

  2024cites this paper
• Depletion of conventional CD4+ T cells is required for robust priming and dissemination of tumor antigen-specific CD8+ T cells in the setting of anti-CD4 therapy

  2024cites this paper
• Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells

  2023cites this paper
• Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

  2023cites this paper
• T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.

  2023cites this paper
• Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha.

  2023cites this paper
• Assessment of interleukin 17A and 23 in the course of bladder cancer and selected benign urological diseases.

  2023cites this paper
• Optimizing the manufacturing and antitumour response of CAR T therapy

  2023cites this paper
• Integrated clinical analysis and data mining assessed the impact of NOX4 on the immune microenvironment and prognosis of pancreatic cancer

  2023cites this paper
• Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance

  2023cites this paper
• Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models

  2023cites this paper
• Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner

  2023cites this paper
• Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models

  2023cites this paper
• Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation.

  2023cites this paper
• Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

  2023cites this paper
• Macrophages as Key Mediators of Trp-1-Specific CD4+ T Cell Therapy for Murine Melanoma

  2023cites this paper
• The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer

  2023cites this paper
• MDR1-expressing CD4+ T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical response

  2023cites this paper
• RORγT agonists as immune modulators in anticancer therapy.

  2023cites this paper
• Increased circulating Th17 cell populations in patients with pancreatic ductal adenocarcinoma

  2023cites this paper
• TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content

  2023cites this paper
• CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy.

  2023cites this paper
• Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials

  2023cites this paper
• Intricacies of TGF-β signaling in Treg and Th17 cell biology

  2023cites this paper
• Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment

  2023cites this paper
• Progressively enhancing stemness of adoptively transferred T cells with PI3Kδ blockade improves metabolism and anti-tumor immunity.

  2023cites this paper
• The application of machine learning methods to the prediction of novel ligands for RORγ/RORγT receptors

  2023cites this paper
• CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours

  2023cites this paper
• Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors

  2023cites this paper
• Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity.

  2023cites this paper
• Defining the mechanisms of action and resistance to the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain models

  2023cites this paper
• Comprehensive analysis of cuproptosis‐related gene expression and positive correlations with CD4+ T cell infiltration in head and neck squamous cell carcinoma

  2023cites this paper
• STING-driven activation of T cells: relevance for the adoptive cell therapy of cancer

  2023cites this paper
• TH17 cell immune adaptation.

  2023cites this paper
• Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

  2022cites this paper
• Tissue-resident glial cells associate with tumoral vasculature and promote cancer progression

  2022cites this paper
• OXPHOS promotes apoptotic resistance and cellular persistence in TH17 cells in the periphery and tumor microenvironment

  2022cites this paper
• Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance.

  2022cites this paper
• An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis

  2022cites this paper
• Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment

  2022cites this paper
• Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

  2022cites this paper
• The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice.

  2022cites this paper
• Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy

  2022cites this paper
• IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer

  2022cites this paper
• Roles of CD4+ T cells as mediators of antitumor immunity

  2022cites this paper
• Immune mechanisms in fibrotic pulmonary sarcoidosis

  2022cites this paper
• Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

  2022cites this paper
• RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers

  2022cites this paper
• NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.

  2022cites this paper